ONVO - Earnings call transcript Q3 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and welcome to the Organovo Holdings Fiscal Third Quarter 2019 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to Mr. Steve Kunszabo, Head of Investor Relations. Please go ahead.

Steve Kunszabo

for thanks and afternoon, joining us. Good to XXXX earnings like welcome you quarter third fiscal our call. to I'd

Joining me will on Crouch; the Q&A. fiscal call this afternoon followed results, CFO, discussion the by Kussman. third the quarter and are Craig Today's with call begin of XXXX our CEO, Taylor

XXXX. Before Reform of afternoon to forward-looking may all I statements to Act the that participants within like things I'd over meaning Private contain Litigation Securities our of turn the Taylor, caution call this

are are expectations, forward-looking include and filings Commission. more and are are that statements subject statements which cause about beliefs in prospects. with discussed statements to the fully Securities and Forward-looking historical facts are could current actual statements not forward-looking expectations Such our our plans Exchange based our the results statements. risks and risks, from and to future upon Such differ

as any specifically we if risks. represent at or Our obligation our light expectations of forward-looking we update in remarks such some do so only to today any our be reviews in statements point today the forward-looking statements considered change. elect to of future, And disclaim and should views even may while

things measures supplemental generally-accepted supplemental also financial financial in prepared for the to these of refer With release to over definition principles. During Taylor. supplemental to financial measures. call, let Please be with referring are accounting measures. we'll certain turn me not These accordance today's that, earnings

Taylor Crouch

also excellent enough net executing with planning on manufacturing that all dose as utilization are key development meet through additional start along fiscal and practices provides preparation. that From clinical our Steve, XXXX This XXXX. objectives calendar in goals to and with fiscal chemistry everyone. our necessary our along perspective, studies, improved us confirming clinical as a for hand controls, and which IND cash Thanks, once the manufacturing and again by of ranging our operating three afternoon, good proof-of-concept with cash progress the start We've we the runway studies, good the steps for year successful I'll operating and noting we're making trials. through XXXX. an includes goes well year

in transplant provide aim liver delay for Ultimately, initial these liver our is disease in metabolism. bridge to implanting related and want patients the patients or often with function bio to unmet errors deficiencies a to to patch of abnormalities who or human disease we the we of a enzyme end By our hope reduce patients tissue printed XD overall options, with condition. areas. including with specific a patches limited select offset group healthy have tissue severe inborn transplant Our treatment restore to these stage

milestones our As are XXXX, interim map I look to planned calendar several in the first to there progress. way filing ahead IND our along

XXXX. also expect it to study development to liver humans. NovoTissues to our conduct our key safety of first of study on a the focus that is meeting of the the intend final our this to of end-stage reasonable potential and use further in more goal support aim The We'll determine disease, treat for studies metabolism. areas target proof-of-concept additional to toxicity in hold We enable the calendar lead with calendar to that second-half to in human We trials. pre-IND XXXX enabling in indication support FDA steps IND start in

has We're Last Finally, about find on submitted comments second medicine until animal quarter beyond. our the directly and has designation. the pursuing an pediatric this the particular received using We forward Type it for makes we what ourselves data to to have IND and depending we drug to the translatable throughout advancing designation we look drug development The clinical regulatory And designation might responded Alpha-X-Antitrypsin respond orphan before predictability prefer deficiency in designation on of to wait successfully we space, with designations late sense. to focused the where In application XXXX. the to we no X a evaluating certainly is drug continue treatment impact we case to drug trials. outcome and this toward this of orphan availing expect our forward FDA analysis, orphan disease, clinical program of in other potential orphan many FDA, orphan of process. move plan Tyrosinemia. to the we're further NovoTissues on how pursuing model FDA's regulatory questions the in disease, whether we and our incentives human may internal the regenerative

number moving We healthy construct, successfully areas. liver evidence AXAT of functionality. in also from plan already of a aimed range proof-of-concept a liver forward same number of two In NovoTissues robust such In AXAT Tyrosinemia, of both we applicability able to last the conducting results also AASLD, tissue known can and liver preliminary known safety globules intend assess publications will the disease continue a our events. we development of to and our third profile continue pre patients the range extended therapeutic the published demonstrated median X retention we've and this studies of who treated clinical tissue pre as have show were major we're reaching across AXAT liver Type Furthermore some misfolded initiated animals. Using characteristic healthy of insoluble end-stage at patches the in as and to had survival awaiting our to to progress rate new studies new potentially as enablement are and liver. explore strategy, address late to meeting a a the generated We communicate have several demonstrate model, scientific studies, To In through and additional transplants year disease liver industry our disease in also clinical an clinical modalities. ongoing tissue an we're likely studies encouraged indications. patch proof-of-concept tissue have remain Type improvement in our how by variance indications with we will that and the in effects during reached broad our pre to the believe of treatment models recap we quarter that our of pathways. performance X including target Tyrosinemia which animal evaluate fiscal our

tissue new opening in IND project also anticipation dosing requirements. proof-of-concept patches pre As of move disease areas. areas. ranging closer focus in scaling studies to liver and clinical promising our we our data dose tissue optimizing in our We're other human on new our will design, up up And we're filings,

we're controls to advancing plan. addition, operational chemistry In our our prepare capabilities manufacturing and

first the of stringent clinical late Our partnership received final note, optimization, of our to Of processes objective for Medicine, implement the a grade internal first-in-human International our is clinical adoption manufacturing trials. encompass range of year well steps These functions including and of in and controls and last through our advance wide quality IIAM. documentation, facilities scale Advancement we manufacturing validation process liver with the Institute equipment

and receive organs research used compassionately procurement human is therapeutic organizations next And for organs of You'll year for recall the over the of IIAM our one these the start the expect world's trials. donated the applications. a prepare and development of as to medical we of in first leading of IND we series that

agreements therapeutic pursue our licensing grants generating bio technology. opportunistically liver derived procurement and advancing While our leading that projects from revenue service The platform we'll leverage printed tissue, also and bioprinter includes custom to generating my Samsara and opportunities and capabilities. continue our Organovo tissue division, XD self modeling from we're placement

clients with from toxicology variety custom to collaborate exploring disease to that projects We also studies. of on modeling continue our a liver applications span

new to both evaluating came of For a which pharma focused toxicity example, with in quarter, large projects, us the third drug two issue. clients back on

results value the National to David Diego, presentation a work UC Vice NASH, through their Chairman translational potential patients the a human at of San NASH-TAG in our reduction non-alcoholic disease short, in in Health of model a of fat treated two tissues We're the and our shared for observed treatments recently of development academic step affects accumulation space. worldwide. detailed of phenotype steatohepatitis, Brenner, disease and for the for few that to of invito tissue NASH developing case. liver One were conference San the compounds in disease on weeks namely XD partners, diseased grant supporting These the development an bioprinted NASH advancing grateful induced in NASH at millions each Dr. ago. these model, and exciting like is a Institutes where liver was who Sciences Health in gave this model. UC promising data then in In This potential in Diego, drug demonstrating for the with the San we U.S. clinical conditions Francisco our groundbreaking

complete Our our that he to a present member, his develop laid tune clinical help and pleased a to to you was innovative Shapiro tissue milestones off we've In functionality with look turn at is soon. clinical to months. Brenner's financial XX out XXXX with to that again fine a over Dr. as I'm Craig in-human next ways liver keen review. trial we're development that, on achieving focus With engaging I our over newest the design, us closing, extensive to expertise board start XX David first well as exploring drug new also presentation. Dr. forward I'll platform. development the the of it good for more in speaking calendar

Craig Kussman

quarter XX% in of line quarter. costs streamlining loss fiscal period. our afternoon, included million our December We Taylor, issuance of year of ATM related the and capital up cash over or to to had million requirements. end $X.X and in $X and summarize of cash $X.X activity the proceeds quick for million and the ago the quarter. these reported the versus offerings. of capital wrap the balance in million fiscal $X.X in progress of a prior reviewing will is million, future $X.X and expenses financing net everyone. I'll third The from in flow swing cash XX% thoughts profile at utilization common considerable posted key million $XX.X stock we improved R&D our profitability good improvement equivalents utilization, with statement total my a of metrics which year quarter net programs; and the Similarly, cash figures net during a working due the operations by of market and income of primarily to our net net bottom Thanks, X.X then our third ATM liquidity the At recap loss and million, in cash a a I'll our we shares trends. favorable a the reduction start case

ATM trades. through we've addition, $X.X XXXX thus million far In already raised calendar in

fiscal million burns commercial and supported The we our market will driven our material As $XX.X capital years facility, R&D operating to permit, access and use With to from opportunistically cash management capital runway and XXXX. fiscal million million funds extend two between million $XX have funds cash in of to plans. to improved by ATM continue sufficient net cash utilization forecast have programs last now revenue And thoughtful we continue through our $XX.X to We rate reduction meet to be the circumstances by facility our the of $XX dynamics for for out available we year versus we'll XXXX. opportunities. IND an the carry our requirements development fiscal net business. believe our and our ATM approximately under in

now $X.X due Moving lower $X.X to administrative and prioritization year-over-year million our the in million, our reported and quarter, development statement fiscal selling, organizational a research the largely XX% first to and R&D lower expenses. third were and costs decrease expenses on expenses general of X% reduction primarily a employee restructuring from projects. expenses, our employee year-over-year focusing during related resulting operating income to We

As our are over reinforce. trends the quarters, expense to next I'd there two we several drivers like important consider

costs. our FDA. clinical organizations liver to the our IND right leading we to research First, take and We'll as level count a rebalance and with to filing fixed of XXXX calendar keep topical variable therapeutic through partner with the good tissue gear we consultants our we'll development balance head effort continue us versus have expert up today to

Second, our study to our enabling our R&D the in we closer therapeutics expect and toxicity toward program line continue as in XXXX. business IND move spend our to we for first IND increasing lead of

services million, lower $X.X the from quarter line, On fewer generated Total which revenue of Organovo third in top and revenue fiscal active the year-over-year research year period. quarter. XX% grant primarily for revenue tissue declined the total contracts due decreased liver prior to

moving to continue custom our model. for the to activity calendar up we the of processes our revenue partly gearing usage of supply conclusion, In to IND expect As unpredictable first look forward back pre shared business of to part profile I'll manufacturing to the studies necessary the our we're are our our we've the and before, successful I With Q&A to and this systems you for things in due with this to facilitate chain, call. be pre-IND months portion the XXXX, on in for quality ahead. ready year. with turn progress this the meeting clinical operator ahead a afternoon's that, FDA updating

Operator

comes Instructions] Wainwright. [Operator question Please from go Ed today ahead. H.C. Our with Arce first

Ed Arce

continued on in Congrats progress the quarter.

perhaps in a questions here So I'll for follow-up. couple of quick and queue have I get the

of confirm perhaps or you in it of IND previous design? how know the program. around this was, and errors optimization talks activities that give your then about lead inborn question could across that and work? you're forward other holistically the give we the you looking and types do tissue sort the updates you're a an approach year, scaling diseases if metabolism basket later discussions us be just of involved to looking that about I enabling filing capture those us update that any this that And to activities of could thinking up for the of at terms number the IND would of think your the and more on the around on can Just

Taylor Crouch

that this broad to is on fact tissue. of interesting our we very range the and we The are the what promising just Your to and function functioning based of does itself. way a approach tease liver first indeed tissue out called referred feel provides normal basket our question planning like capabilities concept a we've the that healthy

list a a broad end-stage are Our broad disease. who into variety liver on this of with patients conditions through disease diseases that of patients start of several strategy transplant interest. have to reached of with These tapping of errors inborn to is including group the list metabolism

areas, test an treatment So we liver also explore first to have in very that list disease importantly our drug to begin trial. important think there this is within deficiency, some hope phenotypes get are no patients strategy gotten a which where really Alpha-X-antitrypsin disease, from other early that range would that end-stage options to a clever arena, but of we to most the on in data

in composition we've rodent up, patches animal most tissue scale in work version that we involved same up experience model size. obviously envisioned in others we these who human the patches a a approaches human most about scale with sense place get surgeons, trials approaches serve these talking believe all regarding will our printing bio smaller into larger which of we to And to launching be human field in a up had environment. of far filing, the transplant of comfortable the question how what second strategy our transplant Your the IND much level clinical how scaling will advance in our radiologists scaled now good models, much we done and The so well and what the this involve tissue structure, to and of but and in process. make order after are have to IND just to facilitate and which tissues well would we're already as we involved might for environment,

Ed Arce

the that? quick size scale queue. think something up So The jump human as had size referred to and or just for a use intended you back I the follow-up I'll previously like in of $X.X

Taylor Crouch

final but stitch can based you of Yes, out, not in units the square size our just somewhere comprised we envision being square the patch can and configurations. our a in in disclosed perhaps units. - we've basically up we're rectangular those bill to that that of looking units closer we're that range just than dollar animal using more of publicly human it building The from together various many of same models, we're print

Operator

Our ahead. go Rahimi Capital next with from Yasmeen question Please ROTH Partners. comes

Yasmeen Rahimi

tissue, have platform. in quantify implementation. actually potential additional XXXX? Can how exciting have number attracted to last we’re have in questions, regards moving as comes me that follow-up months you quite we're fact for the our space the Thank one quite you is you forward is into could patient about the modeling in many you when walk and the you. partners it XX biotechnological NASH projecting and taken Bioprinting my the then before developers liver you How direct - been inner through question if obviously currently variability Two And there very year tissue come is what to are into thinking and that are given vitro question many How specifically is human. many regenerative play.

Taylor Crouch

questions. and Yasmeen for thanks Thanks those

reason organ. is area need the the and to and would to One it of Both in heart it's that liver. in is They that it’s fact as it’s are put And not patches. ideally human, signal to to we premise an of addition in in explore the the very perhaps expected that not we not will regeneration we've in the of effects in - want help have Unfortunately focused significant that of models, on unmet evidence animal it’s healthy patch of we so our host liver show regeneration environment in functioning seen healthier regenerative human a indeed these far expected. see the at human we regeneration models.

to of the case FAH AASLD seen model So onset life us model of help address signals only be the would life panel depending research, to our will functioning NASH than a was believe space dosing really at But is luminary environment at on I that implants human outcomes. and in the a positive NASH on in would impact job we're the expect or who than a important used drugs for once and one that the various into in presented demonstrating Brenner regenerative preclinical or on in we predicting probably sitting drug the more of question lengthy set our and actual the space animal. the do made those Dr. environment. and considerations show to progress and very time we in would functionality his performing model on seen Friedman the the one that the presentation this very relevant disease answer delay patient that more the FAH the regard we've get Organovo's And With the model NASH we've of tissue we’ve our lives encouraging human an AXAT want the in do on one half in or focused disease. modulating encouraged of presented recently obviously were disease which results Dr. most increase tissues expectancy

not than question. And that again along albeit it what of such give clients each also to don't but to mechanism typically large joining a to at a we starting client conditions treat two combination routes. to chemical of by to the clients hardened year with years strategies. of continue clients, look have a either continue with are tox look they NASH or in this have asked We trends We it show to to over work more custom at this drug expect want version of clients action we just guidance fact starting that with their even relevant mentioned the see the with or recently conditions has that a couple at look a us traction to in model just feeding we us for questions of was to induced up these past involving more often terms number that worked

Yasmeen Rahimi

of the of you last be space? ask the therapeutic on also Dr. his Thank for NASH addition in much the vitro mostly would or me involved inviting question one Shapiro development to on in ne in the capabilities he Board. tissue the Will so sort congratulation involvement

Taylor Crouch

the you lucky areas We're very expertise deep he both that of actually mentioned. had in

deep The in and because a nice the knowledge talented First fact obviously having provide recently insights important been and space also for a a us Officer intensively. development to that add and he look buy vitro is this to who but onto Intercept and been development most is NASH of wanted physician liver we studied Medical he the space drug has able Chief board. - with leader modeling foremost at drug having at also as a in bonus strategies our quite client its a

look useful we the So of engaging him answer insights areas the level is board and both business. to on forward your question to providing

Operator

ahead. question with Please comes Raymond Ren Benjamin Our James. from go next

Ren Benjamin

up. and we’re bridge thinking from deficiency there the bit going rear amounts to about color the I color should kind in back be now are maybe how are manufacturing the of the just we bit you thinking you guess little they we that? different should kind about hope one you tissue of about more thinking just Taylor to a type fuel be just we we of might more scale be of be the progress terms where terms along a provide on when can more a were and where those same, been to in what's little to need transplant thinking patients year versus Obviously of the both or

Taylor Crouch

we in mention we've for range vitro that implanting print the up we purposes. it expertise years years fortunate broad into most XX that spent in Organovo viable in And modeling up our to used animal. should printing First our couple of over is I of of that tissues are and abilities tissues increasingly which last developing liver in

it built the CMC and on that expertise a scale larger it we tapped planning skill in set in-house. is through expand ability scientists skills And cells and them company. our really Samsara a work range a the the taking at the on broad of scientifically to across put involves them GMP them our exact shared in a of subsidiary, configuration to of and bioprinting process process here So isolate procure while developed the is therefore lot print this same deep various through

current consumption scale the bioprinter overall and to of trials outlined. related of to of towards we've clinical kind sufficient move but Craig I start that In is expense more operating of some believe have mentioned metrics we think of volume our had our in-house see lines staff expand to we’ll as we as terms currently meet the that capabilities the we materials, the clinic than

Ren Benjamin

Okay. And ahead. then sorry go

Taylor Crouch

the you that And we're surgery. questions of To how much right doses question and would transplant kind material the IDR with with patches ask liver can perform sort dosing we and in what folks we’ll say - this. now I are work would earlier I and laparoscopic physician then deliver relating FDA configurations to discuss and as mentioned hepatologist working to the what to a to the meaningful of approaches answer

We yes have with expert believe I year the these a guess a preliminary questions interactions over and an it we was quite FDA discussions through are ago. over obviously or ago well fine-tuned year

versus a we believe So the our FDA. but to in doses, variability of initial a these trials out our things steps will expect plan of we I that smaller have believe work in that final the not for dosing. good we for larger huge terms have are

Ren Benjamin

bit help can tissues of me in terms that models. duration just you preclinical And produce of these a the function the you understand for little in

take it with been the over necessarily that I'm out patch? to guess follow I the could longest potentially serves what's for just live it this not with that one going So function day the bridge that you could transplant but and able where you've and really is function

Taylor Crouch

liver really remarkable surface which this to XXX published tissue given quite livers. on is the we’ve data to transplanted of rodent is So patches days that human

with be and shoot familiar expect that to and start because that we of to will duration Our a months of environment. a to at regard really might of one for never in actually in measured shortage more meaningful much effect level hope in whom see get patients many that is past waiting Certainly to arguably transplant. a and least transplantation livers now the benefit they'll bridge human functionality to in have

wait possibility handful seeing human in trials. our and things clinically effect the to would The are news what which clinical meaningful. these with what just environment would even see in of opportunity We that we're now transpires commercial for duration will suggested to that believe that of the transplant. effect suggest a need that in we've regard hope longer-term is a got is obviating these see and But would that be all our the evidence meaningful months to we So patients. is good maybe have you of

Ren Benjamin

And I I guess that a surprised bit one final that Tyrosinemia. just using was model back me hear one to you push hereditary for the from FDA were little the on actually

of the all you models fact have guess in look I would make gone As you're back at sure kind other be by the that those that to doing acceptable FDA.

from of mentioned those. studies can would to quite color you new hope been there that bit preclinical think provide a learn that few I little have initiated you just us so a with

Taylor Crouch

Sure had that to the pre-pre-pre-IND the the fact first we extensive with question I’m met going very that FDA based extensively that book encouraging start to for briefing meeting using the animal on about a of animal the and our the were your the components application. that two with FDA was orphan this based data felt drug At kind path that take clinic we in modeling approaches very on that data. we to us submitted we the meeting designation would

and That's And animal on such that a is This see replicating us compelling clinical set the that specific disease the the they more drug to the going like solid disease I and for first why model same IND provide is use on to want to have applicability that time would that they of evidence argue and certainly the to now those functions we the certain space the strategy on before kinds the work. designation back in recipients. but one animal just the data So off now. second go we to the like the Tyrosinemia apple questions that we the human and them evidence is around no designation area. of timelines challenge see that provides human human separate more big the are threshold were and exactly FDA into cost grant they orphan their trial to bites more we we good about had not grant really clinic which data chooses there that Very lucky our they choose upfront. granted to bearing concerns model towards building the the primarily data an in have at to the they for or orphan benefits would designation condition data said animal and using granting of may in will designation or we're modeling a from take-home tissue that the

on we justified We’re in particular just that until designation. that this may the clinic we for sit and are back wait go and

Operator

[Operator Instructions] comes Cross Matthew Please JonesTrading. ahead. from next question go with Our

Matthew Cross

to kind as first kind address? response wanted as Just any make - strategy the I this we of on that from too to but reaching signaling FDA approach this of Tyrosinemia the Ed's with having discreet these of much IEM's agency for off to this regarding to an does response concerns give pause ask out the as don't designation the basket you IND, from I viewed far FDA back the liver question

Taylor Crouch

reached in to who've exposed the do a have range I up reason In we're transplant various those in and hepatologist I believe proof-of-concept as model. do and we separate what transplant and these liver there a has out, be to put in the this as IEM. IEMs will And the the on to investigation described each is us in build how and cause interest that the to possible, strategy going in groups. mean and of diminished think liver plans revolve data them of functionality that us the a focus us and for pre - point. or areas in cases surgeons patients is clinical liver that once several going diagnosed a of maybe I end-stage developed to to disease we've how And meeting what to at we well the showing know starting think for primarily allow studies from as they don't haven't arguments cirrhosis the underlying patient of experience One That need just that's list expanding on patient us they why our a these that we're functionality clinical looking discussions excited got not that in in pre-IND they branch respond around the this even that into question. our tell is pre-IND great list, clinical tissues we'll give those provide as lead got patients as series said, degree to had nuances do patient mentioned function. our to the space I as other animal disease and Matt drilling about around whether FDA quickly tell of and be even many states that in how one much parallel, areas of and indeed indications I the that

quickly we with great is we'll that multiple of armed can this into a opportunities. So believe convince to branch data set strategy that a FDA the be

Matthew Cross

might CMC I of these you're the these live trying as from review, before collection beyond detail talk time detail post into IEMs? able studies hoping what expansion animal around like how really the actually avenues and to appreciate filing process I'm a IND prepare the little studies reach in with into models. us still understand envision for as if slot to you're those pre-IND more preclinical was, studies you of that directions which to that future of be to and was give hoping led kind Basically enough around kind question running conclusions move studies I proof-of-concept next you you these these and may or to my

Taylor Crouch

as different Well, position the different One providing This functionality of all doses range look and showing the in show surgeon of specific that's group we there's and a of to at. want at creative can lot placement heterogeneity physician tissue and examples there's because functioning shape and inserting a patients important and conditions or conditions categories of in into base explore conditions our is to probably it's animals, possible for those of use. different range might the the a patient. functional in tissue in their treating have clarity in range one sicker a Those broad much two tissues to animals, broad conditions. surgical proof-of-concept. among avenues of liver general is, And healthy as aimed our involve

enzymes each these might our effect. animal The able in that deficient measure condition the animal the mean have but enzyme. each been completely other production in deficient of these that's We're and all inborn emitting explore of that in human area conditions animals our like see in in is you'd how - how drug, to provide I animals obviously purposely various to enzymes explore it in an the the version of would of patch conditions patch an certain perform to of enzymes of bred the

we bit tricky All asked pretty Type the question FDA animal back us effect. show the gets a particular X potential of this probably were on the gets little model and the Tyrosinemia to using to

human way would create it disease study can't to in that the You animal. exact we want

come So the edges all around described. can it do is I've the you at way

this And human from senses we're basis were have they, that so humans. and allow honing in to separate to knew grants concerned prefer group on FDA for the data. that about The their a we conclude, evidence should We is response. ODD that is or drug studying our in good yes, that determines the not evaluations

luminaries and the a that very number We rare of of to last the are extremely available Tyrosinemia, the disease we pre-clinical late was it meeting few are clinical November commercially from were one the therapies Type pre or an already that presenting experts. heartened on edge presenting the were clinic and in response present in enthusiastic panel, by the companies AASLD audience fact data at amongst our X we cutting asked there

think humans what FDA proof-of-concept much potential shore have create the as confidence trying to as data enough exploring I that to up worth ultimately we with meetings. a again that these that's so we're now in showing benefit And possible going into

Operator

Our next Please follow-on with Arce is H.C. from a Wainwright. ahead. question Ed go

Ed Arce

that you ask a source whole wanted sourcing organ tissues and with just you Samsara, internal recently that I together part organs It received perhaps about does the compliment optimize with also question the to IIAM. liver about cells, how much. perhaps especially does work but that your I'm the whole all that of stem clinical liver So wondering announcement like in you this use division mentioned and cells you of agreement to and at so how recently entered cells them is this into Thanks bio-wing up? from so and continuing sort sounds the and think your design that as you you scaling least as cells use, to the own get well tissue so

Taylor Crouch

Sure, that's important question. an

our Organizations with not-for-profit OPO's provide was research now has spread them not organs where that deemed for world patience XX be to here donated Organ on organs could sure various is for are with IIAM those for forefront use. to XX timing is group quite works working are announcement strategic They are And lack that the just for believe or making are research And or the States. getting reasons United and of of the them start these transplant across reasons, me a procuring focused procurement delighted of largest the compassionately organs organ the U.S. the a in or let I it's causes. transplant that the as be because groups not applicable Those a with repurposed here do from This deemed So we those now really than every organs IIAM. affect are the potential directed these and group Procurement at the that applicable States. group agencies are organ other quality cell that of used And platform. for Samsara tissues Those to cells of tissue that What an to to cells fact certainly can affect of but a donated isolate human the community the come not provide ultimately be patients our from most really and will second are be donated endorsement model doing the through quite steady and serious have this those in provide transplant supply we we cycle to field. increasingly might potential kind are we group organs blocks and condition. treating transplant high of important our these cannot is what that uses of a saved brought organs. we And - how life research and to the building back is own our ideally that diseases. of comprised we're very

explains that that of hopefully relationship. So the significance

Operator

now session the and question-and-answer disconnect. attending you as today's conference. as the well may concludes you Thank This for presentation

Organovo (ONVO) 7 Feb 192019 Q3 Earnings call transcript